Moxalactam, a new
beta-lactam antibiotic, was given to 35 patients at the Department of Surgery, Cantonal Hospital, St. Gall. The trial period started in April 1980 and ended in October.
Moxalactam was not combined with any other
antibiotic. The
clinical course was observed closely and extensive bacteriological, mycological, and pharmacokinetic studies were carried out to evaluate the new
antibiotic. Most of the patients had an intra-abdominal
infectious disease and primary treatment was surgery. The
antibiotic therapy was started at surgery. A total of 290 different bacteria could be isolated from the 35 patients. 220 isolates were aerobic and 7 0 anaerobic. The minimal inhibitory concentration was calculated for every isolate. In addition, the serum levels of
moxalactam was determined in almost every patient. In 31 patients (88.6%) the
therapy was successful, in 2 patients no evaluation was possible and in 2 patients the
therapy was unsuccessful, including one patient with a primarily
moxalactam-resistant Bacteroides fragilis responsible for
sepsis. In some patients a massive increase in Candida was noted in the urine, stool, or
wound drainage. Primarily
moxalactam-resistant organisms, such as Streptococcus faecalis, were often found alone in the samples taken later in the course of
therapy. An extraordinary change in the fecal flora could be observed during
therapy, but no clinical complications resulted. No specific antifungal
therapy nor any additional
antibiotic against Streptococcus faecalis was necessary.
Moxalactam was well tolerated and side effects were minimal. No impairment of renal function was noticed.